文献速递其他结缔组织病

特发性炎症性肌病患者重症COVID-19的相关因素:COVID-19全球风湿病联盟医生报告登记研究结果

Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
PubMed 文献 · RMD Open · 2022-01-01

基于COVID-19全球风湿病联盟医生报告登记研究,纳入348例特发性炎症性肌病(IIM)成人患者,采用多变量有序logistic回归分析重症COVID-19的相关因素。结果显示年龄较大、高疾病活动度、≥2种合并症、泼尼松龙等效剂量>7.5 mg/天及利妥昔单抗暴露与重症COVID-19独立相关。

要点

  • 348例IIM患者中48%未住院、39%住院未死亡、13%死亡。
  • 年龄每增加10岁、高疾病活动度、≥2种合并症、泼尼松龙等效剂量>7.5 mg/天及利妥昔单抗暴露与重症独立相关。
  • 敏感性分析中男性及2020年10月1日后诊断与结局相关,但主模型未达显著。

核心结论

  • 年龄较大、男性、较高合并症负担、高疾病活动度、泼尼松龙等效剂量>7.5 mg/天及利妥昔单抗暴露与重症COVID-19相关。
  • 这些发现有助于对IIM患者进行风险分层并指导管理决策。

研究设计与样本

  • 研究数据来自COVID-19全球风湿病联盟医生报告登记研究,纳入348例特发性炎症性肌病(IIM)成人患者。
  • 采用3点有序COVID-19严重程度量表:1分未住院、2分住院且未死亡、3分死亡;使用多变量有序logistic回归估计OR。
  • 敏感性分析采用4点有序量表:1分未住院、2分住院未吸氧且未死亡、3分住院吸氧/通气且未死亡、4分死亡。

主要发现

  • 348例患者中48%未住院、39%住院且未死亡、13%死亡。
  • 年龄较大(每增加10岁OR=1.59,95%CI 1.31至1.91)、高疾病活动度(对比缓解,OR=3.50,95%CI 1.25至9.83)、≥2种合并症(对比无合并症,OR=2.63,95%CI 1.39至4.98)、泼尼松龙等效剂量>7.5 mg/天(对比未摄入,OR=2.40,95%CI 1.09至5.28)及利妥昔单抗暴露(对比仅传统合成改善病情抗风湿药,OR=2.71,95%CI 1.28至5.72)与重症COVID-19独立相关。
  • 敏感性分析中男性(对比女性,OR范围1.65至1.83)与重症结局显著相关,2020年10月1日后诊断COVID-19(对比2020年6月15日及之前,OR范围0.51至0.59)与较轻结局显著相关;但主模型中男性(OR=1.57,95%CI 0.95至2.59)及2020年10月1日后诊断(OR=0.61,95%CI 0.37至1.00)未达统计学显著。

关键数值与推荐

  • 重症COVID-19独立相关因素:年龄每增加10岁OR=1.59(95%CI 1.31至1.91)。
  • 高疾病活动度对比缓解OR=3.50(95%CI 1.25至9.83);≥2种合并症对比无合并症OR=2.63(95%CI 1.39至4.98)。
  • 泼尼松龙等效剂量>7.5 mg/天对比未摄入OR=2.40(95%CI 1.09至5.28);利妥昔单抗暴露对比仅传统合成改善病情抗风湿药OR=2.71(95%CI 1.28至5.72)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death. RESULTS: Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65-1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51-0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively). CONCLUSIONS: This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Yeoh SA, Gianfrancesco M, Lawson-Tovey S, et al. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. RMD Open. 2022. PMID: 36100295. doi:10.1136/rmdopen-2022-002508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。